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Genetic and biochemical studies have shown that PARP-1 and poly(ADP-ribosyl)ation play an important role in DNA repair,
genomicstability,celldeath,inﬂammation,telomeremaintenance,andsuppressingtumorigenesis,suggestingthatthehomeostasis
of poly(ADP-ribosyl)ation and PARP-1 may also play an important role in aging. Here we show that PARP-1
−/− mice exhibit a
reductionoflifespanandasigniﬁcantincreaseofpopulationagingrate.Analysisofnoninvasiveparameters,includingbodyweight
gain, body temperature, estrous function, behavior, and a number of biochemical indices suggests the acceleration of biological
aging in PARP-1
−/− mice. The incidence of spontaneous tumors in both PARP-1
−/− and PARP-1+/+ groups is similar; however,
malignant tumors including uterine tumors, lung adenocarcinomas and hepatocellular carcinomas, develop at a signiﬁcantly
higher frequency in PARP-1
−/− mice than PARP-1+/+ mice (72% and 49%, resp.; P<.05). In addition, spontaneous tumors
appear earlier in PARP-1
−/− mice compared to the wild type group. Histopathological studies revealed a wide spectrum of tumors
in uterus, ovaries, liver, lungs, mammary gland, soft tissues, and lymphoid organs in both groups of the mice. These results
demonstrate that inactivation of DNA repair gene PARP-1 in mice leads to acceleration of aging, shortened life span, and increased
spontaneous carcinogenesis.
Copyright © 2008 Tatiana S. Piskunova et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The poly(ADP-ribose) and the poly(ADP-ribose) poly-
merases (PARPs) were discovered about 40 years ago, and
have been shown to be important in many cellular processes,
such as DNA replication, repair, recombination, cell prolifer-
ation and death, gene transcription, telomere maintenance,
inﬂammation, as well as in carcinogenesis [1–6]. There are
seventeen genes encoding PARP enzymes in mammalians,
including PARP-1, PARP-2, PARP-3, and PARP-4/vPARP:
PARP-5/Tankyrases-1 and PARP-6/Tankyrases-2 [7]. The
best studied of these enzymes is PARP-1 that plays a primary
role in the process of poly(ADP-ribosyl)ation. PARP-1 has
been impicated in the pathogenesis of inﬂammatory and
neurodegenerative disorders and cancer [5–9]. Upon DNA
break induction by irradiation or alkylating agents, PARP-
1 binds to DNA break sites and, by using NAD+, catalyzes
poly(ADP-ribose) formation onto nuclear acceptor proteins
[1, 2]. Superactivation of PARP-1 after extensive DNA
damages can result in a damage of metabolic homeostasis
d u et oa ne x h a u s t i o no fN A D + substrate [10]. Previous
studies have demonstrated that deﬁciency or inactivation of
PARP-1 cause a high degree of genomic stability, charac-
terized by aneuploidy, increased sister chromatid exchange,
chromosome gain or loss, and telomere shortening [2, 11].
These data suggest that the defects in the homeostasis of
poly(ADP-ribosyl)ation could accelerate both carcinogenesis
[12] and aging [13]. Grube and B¨ urkle [14]ﬁ r s td e s c r i b e d
a positive correlation between the poly(ADP-ribosyl)ation
capacity of mononuclear blood cells with longevity of mam-
malian species. This correlation was explained in part by
evolutionary sequence divergence [15]. In addition, there are2 Current Gerontology and Geriatrics Research
correlation studies showing that PARP activity is decreased
in aging human samples [16, 17]. Therefore, PARP-1 and
poly(ADP-ribosyl)ation might act as a factor that limits the
rate of aging [6]. However, whether deﬁciency of PARP-
1 and poly(ADP-ribosyl)ation plays a causal role in aging
lacks experimental evidence. In the present study, we set up
a large cohort of mice lacking the major poly(ADP-ribose)
synthesizing enzyme PAPR-1 (PARP-1−/−) to study life span,
aging, and spontaneous tumorigenesis.
2.MaterialandMethods
2.1. Animals
ThePARP-1knock-outmice(PARP-1−/−)[18]andwildtype
mice (PARP-1+/+) were in 129/Sv background and main-
tained at the Department of Carcinogenesis and Oncogeron-
tology, N. N. Petrov Research Institute of Oncology (St.
Petersburg, Russia). Five to seven animals were kept in
polypropylene cages (30×21×10cm), respectively, under
standard light/dark regimen (12 hours light: 12 hours
darkness)at22±2◦Candreceivedstandardlaboratorychow
[19]a n dt a pw a t e rad libitum. Animals were checked daily
by animal care personnel and weekly by a veterinarian. The
study was carried out in accordance with the regulations
for ensuring the humane treatment of animals under the
approval of the Committee on Animal Research of the N. N.
Petrov Research Institute of Oncology.
2.2. Experiments
Seventy three female PARP-1−/− mice (group 1) and 120
PARP-1+/+ mice (group 2) were used for the study. Once
a month, simultaneously with weighting, the amount of
drinking water and consumed food were measured and the
rate of consumed food (grams) per mouse was calculated.
Terms of puberty were estimated based on the age of vagina
opening. Once every 3 months, vaginal smears, taken daily
for 2 weeks from the animals, were cytological examined to
estimate the phases of their estrous function. In the same
period, rectal body temperatures of the mice were measured
with an electronic thermometer, TPEM-1 (KMIZ, Russia).
The animals were observed until their natural death or
were sacriﬁced when moribund. The date of each death was
registered, and the mean life span, the age at which 90% of
the animals died, and the maximum life span were recorded.
2.3. ‘‘Open Field’’ Test of Locomotor Activity
Animals of each group were placed one by one in a plastic
chamber (30×21×10cm), at the bottom of which 5×4
squares(5×5cmeach)weredrawn.Themicewereobserved
moving in an “open ﬁeld” and the following behavioral
parameters were estimated: (1) the number of crossed
squares in the ﬁeld (a square was considered crossed if the
animal stepped over its border with at least 2 paws); (2) the
number of vertical sets (when the animal rose to its hind
paws); and (3) the duration of standing reaction. To exclude
the possibility of smell-associated orientation reaction, the
chamber ﬂoor was wiped with a wet cloth after each animal.
T h em i c ew e r et e s t e da tt h ea g eo f6 ,9 ,1 2 ,a n d1 8m o n t h si n
the daytime from 10 am to 5pm.
2.4. StudyingMuscularStrengthand
PhysicalFatigability
The mice were suspended on a string stretched to an altitude
of 70cm, so that they would hang by the string clutching at it
with their front paws. The time until the moment of fatigue
and fall was registered in seconds. Within 20 minutes, the
mice were suspended again and the time, during which they
managed to hold on, was measured. Discrepancy between
these two indices was regarded as a parameter of physical
restoration.
2.5. Biochemical Analysis
At the age of 4 and 20 months, 10 female mice of each
PARP-1−/− and PARP-1+/+ genotype were sacriﬁced by
decapitation after overnight starvation. Samples of serum
were obtained and stored in the −20◦Cf o rs u b s e q u e n t
analysis. Biochemical parameters in the serum were analyzed
using Flexor Vitalab (Vital Scientiﬁc, the Netherlands) and
Kone 20 (Thermo electron, Labsystems, Finland) analyzers.
2.6. Histopathological Examination
All the animals that died or that were sacriﬁced when mori-
bund were autopsied. At autopsy, their skin and all internal
organs were examined. Any tumors identiﬁed were classiﬁed
according to the recommendation of the International
Agency for Research on Cancer (IARC) as “fatal” (i.e., those
that directly caused the death of animal) or as “incidental”
(for the cases in which animal died of a diﬀerent reasons).
All tumors, as well as the tissues and organs with suspected
tumor development, were excised and ﬁxed in 10% neutral
formalin.Aftertheroutinehistologicalprocessing,thetissues
were embedded in paraﬃn. Thin (5–7μm) histological
sectionswerestainedwithhaematoxylinandeosineandwere
microscopically examined in a coded fashion. Tumors were
classiﬁed according to IARC recommendations [20].
2.7. Statistics
Experimental results were statistically processed by the
methods of variation statistics with the use of STATGRAPH
statistic program kit. The signiﬁcance of the discrepancies
was deﬁned according to the Student-t criterion, Fischer’s
exact method, χ2, nonparametric Wilcoxon-Mann-Whitney,
and Friedman RM ANOVA on Ranks. Student-Newman-
Keuls method was used for all pairwise multiple compar-
isons. Coeﬃcients of correlation were estimated by using the
Spearman method [21]. Diﬀerences in tumor incidence were
evaluated by the Mantel-Hansel log-rank test.
Parameters of Gompertz model were estimated using
maximum likelihood method, nonlinear optimization pro-
cedure [22] ,a n dc u s t o m i z e dc o d ei n“ M A T L A B ” ;c o n ﬁ d e n c eCurrent Gerontology and Geriatrics Research 3
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Figure 1: Age-related dynamics of body weight in PARP-1−/− and
PARP-1+/+ mice. PARP-1−/− and PARP-1+/+ mice were measured
every month for their body weight throughout a period of 23
months. Student’s t test was performed to analyze the statistical
signiﬁcance of the results.
intervals for the parameters were obtained using the boot-
strap method [23].
For experimental groups, the Cox’s regression model
[24] was used to estimate relative risk of death and tumor
development under the treatment compared to the control
groups: h(t,z) = h0 (t)e x p ( zβ), where h(t,z)a n dh0 (t)
denote the conditional hazard and baseline hazard rates,
respectively, β is the unknown parameter for treatment
group, and z takes values 0 and 1, being an indicator variable
for two samples—the control and treatment group.
Semiparametric model of heterogeneous mortality [25]
was used to estimate the inﬂuence of the treatment on frailty
distribution and baseline hazard.
3.Results
3.1. Age-Related Body Weight Dynamics
The mean body weight of mice increased with age both
in the PARP-1+/+ and PARP-1−/− groups, exceeding at 12
months the body weight of 3-month-old animals by 25% in
the PARP-1+/+ group, and by 30% in the PARP-1−/− group.
Although there were no consistent diﬀerences in the mean
body weight between the groups until the age of 21 months,
in their later life, the mean body weight of PARP-1−/− mice
exceeded the body weight of the PARP-1+/+ mice (P<. 05,
Figure 1).
3.2. Age-Related Dynamicsof
Food Consumption
Regular measurement did not reveal any signiﬁcant diﬀer-
ences in the amount of food consumed between the PARP-
1+/+ and PARP-1−/− mice. It was practically the same during
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Figure 2: Age-related dynamics of body temperature in PARP-
1−/− and PARP-1+/+ mice. Bars represent the body temperature of
PARP-1−/− andPARP-1+/+ miceatindicatedage.Student’st test was
performed to analyze the statistical signiﬁcance of the results.
the all period of observation and varied from 2.5 ± 0.17 to
4.5 ±0.91g of food per mouse per day.
3.3. Age-Related Dynamicsof
Body Temperature
An age-related decrease in body temperature was observed
both in PARP-1+/+ and PARP-1−/− mice. PARP-1−/− mice
had signiﬁcantly higher body temperature than PARP-1+/+
mice at the age of 5, 8, and 20 months (Figure 2).
3.4. Age-Related Dynamicsof EstrousFunction
Puberty appeared earlier in PARP-1−/− mice than in the
PARP+/+ group. The age of vagina opening was 24±0.2 days
and25±0.3days,respectively(P<. 05).Investigationsofthe
estrous function were repeatedly performed every 3 months,
starting when the mice were 3 months of age. The following
parameters of the estrous function were estimated: duration
of the estrous cycle, the relative number of short (less than
5 days) and long (over 5 days) estrous cycles, as well as
the relative number of animals with irregular cycles. Estrous
cycle length was increased with age in both groups. However,
the estrous cycle length was greatly increased in PARP-1−/−
mice, exceeding that of the level in PARP-1+/+ mice by 18%
at the age of 17 months (Table 1). It is worthy noting that at
the age of 20 months, the number of PARP-1−/− mice with
irregular cycles was signiﬁcantly higher compared to PARP-
1+/+ mice (72% and 30%, resp., P<. 002). Thus, PAPR-1
deﬁciency resulted in the acceleration of age-related loss of
the estrous function.
3.5. Age-Related Dynamicsof
BehavioralParameters
During aging, a gradual decrease in locomotor activity in
both parameters recorded (the number of crossed squares
and the number of standing reaction) was observed in both4 Current Gerontology and Geriatrics Research
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Figure 3: Age-related locomotor activity (“open ﬁeld” test) in
PARP-1−/− and PARP-1+/+ mice. PARP-1−/− and PARP-1+/+ mice
were tested for their behavior by “open ﬁeld” at the indicated
age. The vertical axis represents the number of crossed squares
at indicated age. Student’s t test was performed to analyze the
statistical signiﬁcance of the results.
groupswhereasstandingtime,onthecontrary,wasincreased
(Figures 3–6). At the age of 3 and 6 months, PARP-1−/−
mice crossed squares 18% (P<. 01) and 37% (P<. 01)
frequently than PARP-1+/+ mice, respectively. The number
of the standing reaction that PARP-1 knock-out mice made
exceeded that in controls: 47% at the age of 3 months (P<
.05), 87% at 6 months (P<. 01), and 49% at 17 months
(P<. 01). The duration of the standing reaction in 6-month-
old knock-out mice was only 40% of the control. The time of
clutching to a string (physicalforceparameter) wasgradually
reduced with the age in both groups (Figure 6). In the PARP-
1−/− mice, the duration of both the ﬁrst and the second
suspension at the age of 3 and 6 months was shorter than
in control mice. These observations suggests that “young”
PARP-1−/− mice are more active and mobile, but they are
physically weaker than PARP-1+/+ mice. With aging, their
overactivityseemstodeclinefasterasthediﬀerences between
both groups disappeared.
3.6. Age-Related Dynamicsof
Biochemical Parameters
The dynamics of biochemical parameters in the serum
of overnight fasting PARP-1−/− and PARP-1+/+ mice is
presented in Table 2. The level of total proteins was lower in
PARP-1−/− mice in comparison with PARP-1+/+ mice at the
age of 4 months (P<. 05) as well as at 20 months (P<. 01),
in part, due to a reduction in albumin level (P<. 05). In the
knock-out mice of both age groups, hypocalcaemia was also
found (P<. 01), perhaps due to albumin reduction leading
to decrease in the level of the total calcium binding proteins.
A decrease in serum levels of uric acid was observed in the
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Figure 4: Age-related locomotor activity (“open ﬁeld” test) in
PARP-1−/− and PARP-1+/+ mice. PARP-1−/− and PARP-1+/+ mice
were tested for their behavior by “open ﬁeld” at the indicated age.
The vertical axis represents the number of vertical sets at indicated
age. Student’s t test was performed to analyze the statistical
signiﬁcance of the results.
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Figure 5: Age-related behavior (standing reaction duration) in
“openﬁeld”testinPARP-1−/− andPARP-1+/+ mice.Theverticalaxis
representsthestandingreactiondurationatindicatedage. Student’s
t test was performed to analyze the statistical signiﬁcance of the
results.
old PARP-1−/− mice as compared to PARP-1+/+ animals (P<
.001). Four-month-old PARP-1−/− mice showed a reduced
activity of lactate dehydrogenase in the serum as compared
with PARP-1+/+ mice of the same age (P<. 05). In the
4-month-old knock-out mice, the level of α-amylase was
also decreased compared to PARP-1+/+ mice (P<. 002)
although at the age of 20 months, the α-amylase level was
not signiﬁcantly diﬀerent between both groups. There was a
tendency toward the reduction in an activity of some otherCurrent Gerontology and Geriatrics Research 5
Table 1: Age-related dynamics of estrous functional parameters in PARP-1−/− and PARP-1+/+ mice.
Age (months) Number of mice Length of estrous cycles (days) Rate (%) of Number of mice with irregular cycles (%)
<5d a y s 5 – 7d a y s >7d a y s
PARP-1+/+
23 7 6 .7 ±0.34 14 52 34 18
52 7 5 .55 ±0.50a 41 36 23 22
83 1 6 .08 ±0.42b 33 42 25 35
14 18 7.30 ±1.03 20 50 30 50
17 39 7.42 ±0.41 13 45 42 23
20 27 6.1 ±0.35 19 65 16 30
PARP-1−/−
23 4 7 .4 ±0.49 5 59 36 13
52 3 6 .64 ±0.45a 23 50 27 17
82 2 6 .59 ±0.56a 32 36 32 27
14 18 7.91 ±0.86 27 18 55 44b
17 27 8.72 ±0.50∗ 17 28 55 11
20 18 5.7 ±0.56 14 72 14 72∗∗
Signiﬁcant in comparison with control: ∗P<. 05, ∗∗ −P<. 001.
The diﬀerence from the parameter at the age of 17 months in the same group: a: P<. 01, b: P<. 05.
enzymes studied in PARP-1−/− mice as compared to PARP-
1+/+ ones, suggesting a general metabolism reduction in
PARP-1knock-outmice.Therewasnosigniﬁcantdiﬀerences
in glucose and lipid levels between PARP-1−/− and PARP-
1+/+ mice at young and old age (Table 2).
3.7. SurvivalandLife SpanofMice
The mean and maximum life span of mice in the PARP-
1−/− mice was reduced by 13.3% and 16.4%, respectively,
as compared with these of PARP-1+/+ mice (P<. 0002)
(Table 3). According to the log-rank test [26], the diﬀerence
in life span distributions between groups of PARP-1+/+ mice
and PARP-1−/− mice was signiﬁcant with P<. 00000108
(χ2 = 23.8o n1d e g r e eo ff r e e d o m ) .I nt h eP A R P - 1 −/−
group, mean life span of 10% most long-lived mice, were
signiﬁcantly shorter than that of wild type mice. The survival
of PARP-1−/− female mice was compared to the PARP-1+/+
femalemiceusingtheGompertzmodel[27].Theconditional
mortality and survival functions for this model are given by
the formulas:
μ(x) = β exp

α

x − x0

,
S(x) = exp

β
α

1 − exp

α

x −x0


.
(1)
Parameters β and α represent the initial level of mortality
and the rate of aging of the population. The mortality
rate doubling time (MRDT) is equal to log(2)/α.E s t i m a t e d
parameters of this model with conﬁdence intervals are given
in Table 3. While the initial levels of mortality for both
groups of mice were the same, the aging rate of the PARP-
1−/− population was greater than PARP-1+/+ mice. The
MRDT was shorter in the PARP-1−/− mice as compared to
0
50
100
150
200
250
300
350
400
450
500
H
u
n
g
d
u
r
a
t
i
o
n
(
s
)
3 6 17 20 21
Age (months)
PARP-1+/+ ﬁrst measurement
PARP-1−/− ﬁrst measurement
PARP-1+/+ second measurement
PARP-1−/− second measurement
∗ P<. 05
∗∗ P<. 01 ∗∗
∗∗ ∗
∗∗
Figure 6: Age-related holding strength of PARP-1−/− and PARP-
1+/+ mice.ThehungonthestringdurationofPARP-1−/− andPARP-
1+/+ mice was tested at the ages indicated by their holding a string,
and the duration (in second) of holding a string was recorded.
Student’s t test was performed to analyze the statistical signiﬁcance
of the results.
the PARP-1+/+ group. The survival curve of PARP-1−/− mice
was signiﬁcantly shifted to left (Figure 7) as compared to the
survival curve of the PARP-1+/+ group.
3.8. SpontaneousTumor Development
At the autopsy, tumors were observed in 53 of 73 PARP-
1−/− mice (73%) and in 79 of 103 PARP-1+/+ animals (77%)
(Table 3). However, the incidence of malignant tumors was
higher by 20.5% in the knock-out mice compared to the6 Current Gerontology and Geriatrics Research
Table 2: Age-related dynamics of biochemical parameters in the serum of PARP-1−/− and PARP-1+/+ mice.
Parameters PARP-1+/+ PARP-1−/−
4m o n t h s ,n = 10 20 months, n = 10 4 months, n = 10 20 months, n = 10
Total protein, g/l 45.19 ±1.15 48.33 ±1.10 41.88 ±1.47a 25.22 ±0.46c,##
Albumin, g/l 21.69 ±0.52 22.04 ±0.42 19.18 ±1.13∗ 20.99 ±0.29#
Glucose, mM/l 7.27 ±0.30 6.89 ±1.33 7.51 ±0.60 8.31 ±1.57
Cholesterol, mM/l 3.09 ±0.09 2.86 ±0.08 2.86 ±0.17 2.83 ±0.15
Triglycerides, mM/l 0.89 ±0.04 0.88 ±0.08 0.75 ±0.07 1.00 ±0.29
Urea, mM/l 10.46 ±0.43 9.33 ±0.27 8.79 ±0.94 10.31 ±0.41
Creatinine, μM/l 31.70 ±1.34 32.17 ±3.81 27.83 ±1.68 31.45 ±6.0
Uric acid, μM/l 43.60 ±5.46 133.92 ±8.94c 54.10 ±21.55 66.27 ±8.10###
Calcium, mM/l 1.87 ±0.05 2.09 ±0.03b 1.43 ±0.16∗∗ 1.98 ±0.04b#
Alanine-amino-transferase. U/l 56.50 ±4.85 43.42 ± 2.48a 50.82 ±4.48 44.73 ±5.62
Aspartate-amino-transferase, U/l 341.80 ±40.62 231.25 ± 21.86a 259.33 ±25.93 209.36 ±16.38
Alkaline phosphatase, U/l 122.80 ±10.21 129.83 ±17.17 125.67 ±8.03 92.00 ±10.76a
Lactate dehydrogenase, U/l 1330 ±140.93 897.42 ±83.54b 917.91 ±131.33∗ 780.64 ±44.0
γ- Glutamyl-transferase, U/l 6.38 ±1.92 4.55 ±0.29 4.9 ±0.40 5.38 ±0.6
α-Amylase, U/l 1518.33 ±59.93 2519.17 ±336.99b 542.00 ±186.38∗∗∗ 2802.0 ±562.86b
Signiﬁcant in comparison with the control of the same strain at the age of 4 months: a: P<. 05; b: P<. 01; c: P<. 001.
Signiﬁcant in comparison with the PARP-1+/+ at the age of 4 months: ∗: P<. 05; ∗∗: P<. 01; ∗∗∗: P<. 002.
Signiﬁcant in comparison with the PARP-1+/+ at the age of 20 months: #: P<. 05; ##: P<. 01; ###: P<. 001.
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Figure 7: Empirical and approximated by Gompertz model
survival curves of PARP-1−/− and PARP-1+/+ mice. Surviving mice
in each group were presented as percentage as a function of age.
wild type controls (P<. 001). The diﬀerence in life span
distributionsbetweentumor-bearingfemalePARP-1+/+ mice
and PARP-1−/− female mice was signiﬁcant with P<
.00000842 (χ2 = 19.8 on 1 degree of freedom). As shown
in Table 3, the mean life spans of tumor-bearing PARP-1−/−
mice were signiﬁcantly shorter than that in PARP-1+/+ mice.
The mean life span of the most long living 10% of the knock-
out survivors was also shorter than that of the control mice.
The level of initial mortality (parameter β of the Gompertz
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Figure 8: Total tumor yield curves for PARP-1−/− and PARP-1+/+
mice. Number of tumor-bearing mice in each group were presented
as percentage as a function of age.
model) was signiﬁcantly greater for the group of wild type
mice. In addition, the rate of population aging was higher
and MRDT was lower in the PARP-1−/− tumor-bearing mice
as compared to the PARP-1+/+ group. The total tumor yield
curve for PARP-1−/− mice was signiﬁcantly shifted to the left
as compared to the curve of PARP-1+/+ mice (Figure 8).
The data on tumor sites, type, and latency in both
groupsaresummarizedinTable 4.Themostfrequenttumors
were nonepithelial uterine tumors (mostly polymorphicCurrent Gerontology and Geriatrics Research 7
Table 3: Parameters of survival, life span and tumorigenesis in PARP-1−/− and PARP-1+/+ mice.
Parameters PARP-1+/+ PARP-1−/−
Number of mice 103 73
Mean life span (days, mean±S.E.M.) 678 ±14.2 588 ±14.4∗∗
Median (days) 686 597
Mean life span of last 10% of survivors (days) 919 ±11.6 778 ±14.3∗∗
Maximum life span (days) 983 822
Aging rate, α (days−1) 0.00771 (0.00760; 0.00782) 0.00932 (0.00926: 0.00956)∗
MRDT (days) 89.88 (88.6; 91.22) 74.36 (72.53; 74.89)∗
Number of tumor-bearing mice 79 (76.7%) 53 (72.6%)
Number of malignant tumor-bearing mice 48 (46.6%) 49 (67.1%)∗∗∗
Mean life span of tumor-bearing mice (days, mean ± S.E.M.) 706 ±17.6 612 ±19.2∗∗
Total number of tumors 120 82
Total number of malignant tumors 59 (49.2%) 59 (72.0%)∗
α in Gompertz model: R = R0(exp)αt,w h e r eR0 =mortality rate in the time of t = 0, 95% conﬁdence limits are given in parentheses; MRDT, mortality rate
doubling time.
The diﬀerence with the PARP-1+/+ is signiﬁcant: ∗: P<. 05; ∗∗: P<. 002; ∗∗∗: P<. 001.
sarcomas, as well as vascular tumors, namely, cavernous
hemangiomas and hemangiendotheliomas) both in PARP-
1−/− and PARP-1+/+ mice. Epithelial uterine tumors
(polyps and adenocarcinomas) were less common. Ovarian
granulosa-theca cell tumors were frequently observed in
PARP-1+/+ mice but not in PARP-1−/− animals. Heman-
giomas and hemangioendotheliomas have been found in
other organs (liver, subcutaneous tissue). Moreover, both
PARP-1+/+ and PARP-1−/− mice developed epithelial tumors
of the lung (adenomas, adenocarcinomas) and of the liver
(hepatocellular carcinomas). In total, 120 cases of tumors in
the PARP-1+/+ group, and 82 cases of tumors in PARP-1−/−
group were observed.
3.9. MathematicalModeling of the Results
The Cox regression model [24] was used to estimate relative
risk of death for female PARP-1−/− mice compared to the
PARP-1+/+ group:
h(x,z) = h0 (x)exp(zβ), (2)
where h(t,z)a n dh0 (t) denote the conditional hazard
and baseline hazard rates, respectively, β is the unknown
parameter for treatment group, and z takes values 0 and
1, being an indicator variable for two samples—the control
(PARP-1+/+) and group of interest (PARP-1−/−). It can be
seen that for all subgroups, the relative risk of death is
higher for the PARP-1−/− mice compared to PARP-1+/+ mice
(Table 5). The highest risk was estimated for the fatal-tumor-
free mice.
Asemiparametricmodelofheterogeneousmortality[25]
was used to compare PARP-1−/− female mice to the group of
the wild type female mice in terms of frailty distribution and
baseline hazard. The PARP-1+/+ group was considered as the
control. Survival and mortality rate functions are given by
the formulas:
SPARP(x)
=

1+rγ

SWT(x)
−σ2
−1

+rγσ2α
β

exp

β

x−x0

−1

−1/γσ2
,
μPARP (x)
=
rμWT(x)SWT(x)
−σ2
+rα exp

β

x −x0

1+rγ

SWT(x)
−σ2
− 1

+γrσ2(α/β)

exp

β

x −x0

−1
.
(3)
Parameter σ2 indicates the presence of heterogeneity in the
control population. Diﬀerences in the baseline hazard are
controlled by parameters α and β. Parameter α reﬂects
permanent (constant) decrease or increase of the baseline
hazard compared to the control group, depending on
whether α is greater or less than zero. Parameter β describes
the ampliﬁcation or disappearance of the α-eﬀect, according
to whether β is greater or less than zero. Diﬀerences in the
frailty distribution are controlled by parameters r and γ.
Parameter r<1 shows an increase in the average robustness,
while r>1 indicates an accumulation of frail individuals in
thepopulationcomparedtothePARP-1+/+ group.Parameter
g / =1 shows an increase (g>1) or decrease (g<1) in the
population heterogeneity.
To compare the survival function for PARP-1−/− mice
to the PARP-1+/+ group, three speciﬁcations of the model
were considered. The ﬁrst one deals only with the diﬀerences
in the average frailties of the populations (α = 0, r / =1,
γ = 1). With the second speciﬁcation, diﬀerences in
the mean of the frailty distributions are accompanied by
diﬀerences in the baseline hazards (α / =0, β = 0, r / =1,
γ = 1). The third speciﬁcation describes diﬀerences in
survival patterns between the groups of interest and the
control group as a combination of diﬀerences in the baseline
hazard and both parameters of the frailty distribution8 Current Gerontology and Geriatrics Research
Table 4: Tumor site and type in PARP-1−/− and PARP-1+/+ mice.
Tumor localization and type PARP-1+/+ PARP-1−/−
Number of tumor-
bearing mice (%) Survival, days Number of tumor-
bearing mice (%)
Survival, days
Uterus
Sarcoma 37 (36%) 713±21.0 28 (38%) 659±22.9
Adenocarcinoma 5 (5%) 799±41.2 5 (7%) 709±33.5
Hemangioma 19 (18%) 761±29.9 1(1%)∗∗∗ 679
Hemangioendothelioma 3 (3%) 635 2 (3%) 664
Polyp 8 (8%) 718±65.6 2 (3%) 601
Ovary
Adenocarcinoma 1 (1%) 961 —
Granulesa-theca
cell tumor 12 (12%) 692±52.0 1 (1%)∗∗ 734
Hemangioma 5 (5%) 798±71.8 6 (8%) 668±55.1
Cystadenoma 2 (2%) 878±43.8 1 (1%) 534
Mammary gland Adenocarcinoma 3 (3%) 748±163.4 4 (6%) 480±26.9
Lung Adenocarcinoma 4 (4%) 596±54.8 7 (10%) 480±26.9
Adenoma 8 (8%) 702±72.5 4 (6%) 749±12.7
Liver
Hepatocellular
carcinoma 3 (3%) 810±20.6 6 (8%) 664±21.4∗∗∗
Hemangioendothelioma — 2 (3%) 630±35.6
Haemangioma 3 (3%) 923±53.8 2 (3%) 628
Haematopoietic
system
Malignant lymphoma 5 (5%) 711±37.1 6 (8%) 593±40.1∗
Thymoma — — 1 (1%) 208
Soft tissue
Subcutaneous
angiosarcoma 1 (1%) 788 —
Hemangioendothelioma 1 (1%) 414 2 (3%) 497±103.1
Skin Squamous-cell
carcinoma —— 1 ( 1 % ) 392
Colon Adenocarcinoma — 1 (1%) 393
Signiﬁcant in comparison with the PARP-1+/+: ∗: P<. 05; ∗∗: P<. 01; ∗∗∗: P<. 001.
Table 5: The Cox’s model parameters for diﬀerent subgroups of PARP-1+/+ and PARP-1−/− mice.
Hazard PARP-1−/− versus PARP-1+/+ Be x p ( β)s e ( β)p
All mice 0.83 2.3 0.18 2.10e-06
Mice with tumors 0.91 2.47 0.21 1.50e-05
Mice with fatal tumors 0.93 2.54 0.24 9.40e-05
Mice with nonfatal tumors 0.97 2.65 0.27 3.90e-04
Table 6: Comparison of three models using the likelihood ratio method.
r, σ2 α, r, σ2 α, β, r, γ, σ2
−LogLik 1026.77 1021.48 1009.32
P 5.710213184310087e-04 2.28817665292e-03 —∗
∗ The estimated parameter values of this speciﬁcation are presented in Table 7.
Table 7: Estimated values of parameters with conﬁdence intervals.
Parameter α BR Γ σ2
Value 2.33e-06 9.92e-06 1.85 0.17 0.99
CI (2.31e-06; 2.36e-06) (9.87e-06; 9.94e-06) (1.81; 1.87) (0.16; 0.19) (0.97; 1.03)Current Gerontology and Geriatrics Research 9
Table 8: Eﬀects of PARP-1 knockout in female mice.
Parameter PARP-1−/− versus PARP-1+/+ Comment
Body weight Increased after the age of 21 months Accelerated aging
Food consumption No diﬀerence No eﬀect
Body temperature Increased Accelerated aging
Maturation (vagina opening) accelerated Accelerated maturation
Estrous function Rate of mice with irregular cycles increased Accelerated aging
Locomotor activity
Young −/− mice more active, but more
physically weak than +/+ mice;
accelerated aging
No. of crossed squares Increased
N o .o fv e r t i c a lr a c k s Increased
Duration of standing reaction Decreased
Duration of the 1st and 2nd suspension time Decreased
Biochemical parameters
Total protein Decreased with age
Accelerated aging
Uric acid Decreased at the age of 20 months
Calcium level Decreased at the age of 4 months Prone to osteoporosis
Alanine aminotransferase No age-related decrease
Disturbance in the age pattern
Lactate dehydrogenase No age-related decrease
α-amylase Decreased at the age of 4 months Accelerated aging
Mean life span Reduced
Accelerated aging
Mean life span of last 10% of survivors Reduced
Maximum life span Reduced
Aging rate Increased
MRDT Reduced
No. of malignant tumor-bearing mice Increased
Progression of carcinogenesis
Total number of malignant tumors Increased
(α / =0, β / =0, r / =1, γ / =1). Because these speciﬁcations are
nested, the likelihood ratio statistics are used to determine
which one gives the best ﬁt to the data. The parameter
estimates were obtained using maximum likelihood method,
nonlinear optimization procedure [22], and a customized
code in “MATLAB”; conﬁdence intervals for the parameters
were obtained using the bootstrap method [23]. The third
speciﬁcation of the model corresponds to the data better
than the others (Table 6). The estimated parameter values
of this speciﬁcation are presented in Table 7. The PARP-
1+/+ control group was heterogeneous (parameter σ2 / =0).
The group of PARP-1−/− mice had slightly increased baseline
hazard compared to the control group (parameters α>0,
β>0). The PARP-1−/− group is frailer on average (r>1)
and more homogeneous (γ<1), compared to the wild type
mice.
4.Discussion
There is constant DNA damage caused by endogenous and
exogenous sources and DNA lesions accumulate with age in
individuals. The eﬃcacy of DNA repair plays an important
role in aging and in aging-related pathological changes,
including cancer [28–33]. Recent studies using knock-out
mice defective for various nucleotide excision repair genes
revealed a crucial role of DNA repair as a longevity assurance
pathway [8, 28]). PARP-1 is DNA nick senor and responds
very rapidly to single-stranded DNA breaks. PARP-1 is
functionally associated with several DNA repair pathways
[8, 34]. An obvious question is whether the downregulation
of PARP-1 or PAR formation would be a causal factor for
aging phenotype or aﬀecting longevity.
In the current study, we investigated the role of PARP-1
in aging and used PARP-1+/+ and PARP-1−/− female mice of
the 129/Sv background and monitored them for the period
over 24 months. The reason to use females is that female
mice are less aggressive than males and can be grouped as a
larger cohort to make more powerful statistical comparisons,
and, moreover, we can monitor estrous cycles, a reliable
noninvasive parameter of aging [35]. Interestingly, we found
that the mean life span of all PARP-1−/− mice and also the
mean life span of the last 10% survivors were signiﬁcantly
reduced in comparison with the respective wild type control
groups (Table 3). The same tendency was also observed
during the analysis of the maximum life span and median
life span. The aging rate was signiﬁcantly increased and
the mortality rate doubling time was shortened in PARP-
1−/− mice as compared with PARP-1+/+ mice. In addition,
monitoring of estrous function in the PARP-1−/− mice
revealed an accelerated aging of the reproductive function10 Current Gerontology and Geriatrics Research
as compared to PARP-1+/+ mice. As summarized in Table 8,
PARP-1 deletion accelerated aging, as is revealed by many
age-related changes, such as body weight and temperature,
locomotoractivity,andphysicalstrength.Thesedataindicate
that PARP-1 deﬁciency or low PAR formation leads to
acceleration of aging, reduction of life span, and early onset
of tumor development. These results are in good agreement
with the observations on obesity and increased metabolism
rate in the PARP-1 knock-out mice [18]. Whereas aged
PARP-1+/+ mice showed an increase of the serum level of
the uric acid that has antioxidant properties [36, 37], which
might reﬂect an antiaging mechanism, PARP-1 knock-out
mice did not show age-related increase in the level of uric
acid. Instead, the uric acid level was two-fold less than that
in the wild type mice at the age of 20 months. Finally,
these data are in agreement with the study of Grube and
B¨ urkle [14] who described a positive correlation between
the poly(ADP-ribosyl)ation capacity of mononuclear blood
cells with longevity of mammalian species and also with
additional correlation studies showing that PARP activity is
decreasedinaginghumansamples[16,17]).Thisconclusion
is also consistent with the notion that the eﬃcient DNA
repair, proper poly(ADP-ribosyl)ation, and the life span are
positive, correlated during aging (See reviews by B¨ urkle et al.
[38, 39]; Hoeijmakers [33]).
In addition to the change of aging-related physiological
parameters, tumor development is a pathological process
that is also associated with aging. While it could be
caused by a deﬁciency DNA repair and genomic instability,
other molecular pathways including cell cycle control, gene
transcription, and environmental exposure also play an
important role. The major tumor types observed in the
p r e s e n ts t u d y ,s u c ha st u m o r si nt h eu t e r u s ,m a m m a r y
gland, lung, and liver have been reported in PARP-1 deﬁcient
mice in previous studies using recombinant genetic mutants.
PARP-1 knock-out mice do not often develop spontaneous
tumors,whereasinDNArepairdeﬁcientbackground, PARP-
1 knock-out mice develop a high frequency of tumors. For
example, in the Ku80+/− background, a high frequency of
liver cancer was observed [40], whereas in p53 heterozygous
and homozygous background, PARP-1 null mice develop a
variety of tumors, including mammary gland carcinoma,
l u n gc a n c e r ,a sw e l la sb r a i nt u m o r s( s e e[ 2, 41]). The high
frequency of uterine neoplasm in PARP-1−/− female mice is
reminiscentofapreviousreportcorrelatingthelossofPARP-
1 and development of endometrial carcinomas in humans
[42].
In summary, our study using a genetically engineered
animal model has demonstrated that knock-out of PARP-
1 leads to acceleration of aging, reduction of life span, as
well as to earlier and more aggressive tumor development,
indicating that DNA repair molecule PARP-1 and its role in
metabolism of poly(ADP-ribose)ation positively contribute
to the longevity.
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